Emotion-based decision-making in healthy subjects: short-term effects of reducing dopamine levels

[1]  T. Robbins.  Chemistry of the mind: Neurochemical modulation of prefrontal cortical function , 2005, The Journal of comparative neurology.

[2]  Jerome R. Busemeyer,et al.  Using Cognitive Models to Map Relations Between Neuropsychological Disorders and Human Decision-Making Deficits , 2005, Psychological science.

[3]  A. Bechara.  Decision making, impulse control and loss of willpower to resist drugs: a neurocognitive perspective , 2005, Nature Neuroscience.

[4]  N. Volkow,et al.  The neural basis of addiction: a pathology of motivation and choice. , 2005, The American journal of psychiatry.

[5]  C. O'brien.  Anticraving medications for relapse prevention: a possible new class of psychoactive medications. , 2005, The American journal of psychiatry.

[6]  Karen I. Bolla,et al.  Neural substrates of faulty decision-making in abstinent marijuana users , 2005, NeuroImage.

[7]  Olga V. Demler,et al.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. , 2005, Archives of general psychiatry.

[8]  P. Cowen,et al.  The effects of a branched chain amino acid mixture supplemented with tryptophan on biochemical indices of neurotransmitter function and decision-making , 2005, Psychopharmacology.

[9]  P. Laurienti,et al.  Long-term heavy marijuana users make costly decisions on a gambling task. , 2004, Drug and alcohol dependence.

[10]  J. Swanson,et al.  Dopamine in drug abuse and addiction: results from imaging studies and treatment implications , 2004, Molecular Psychiatry.

[11]  R. Rogers,et al.  Effects of beta-adrenoceptor blockade on components of human decision-making , 2004, Psychopharmacology.

[12]  T. Robbins,et al.  l-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson’s disease , 2003, Neuropsychologia.

[13]  Kent A. Kiehl,et al.  Orbitofrontal cortex dysfunction in abstinent cocaine abusers performing a decision-making task , 2003, NeuroImage.

[14]  J. Lieberman,et al.  Impairments in perceptual competency and maintenance on a visual delayed match-to-sample test in first-episode schizophrenia. , 2003, Archives of general psychiatry.

[15]  B. Dubois,et al.  Motivation, reward, and Parkinson’s disease: influence of dopatherapy , 2002, Neuropsychologia.

[16]  J. Richards,et al.  Acute Administration of d-Amphetamine Decreases Impulsivity in Healthy Volunteers , 2002, Neuropsychopharmacology.

[17]  M. Stitzer,et al.  Cognitive impairment in methadone maintenance patients. , 2002, Drug and alcohol dependence.

[18]  A. Nieoullon.  Dopamine and the regulation of cognition and attention , 2002, Progress in Neurobiology.

[19]  P. Cowen,et al.  A dose-finding study on the effects of branch chain amino acids on surrogate markers of brain dopamine function , 2002, Psychopharmacology.

[20]  Steven W Anderson,et al.  Decision-making deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers , 2001, Neuropsychologia.

[21]  N. Ben-Jonathan,et al.  Dopamine as a prolactin (PRL) inhibitor. , 2001, Endocrine reviews.

[22]  T. Robbins,et al.  Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. , 2001, Cerebral cortex.

[23]  P. Cowen,et al.  Tyrosine depletion attenuates dopamine function in healthy volunteers , 2001, Psychopharmacology.

[24]  T. Robbins,et al.  The effects of d-amphetamine, chlordiazepoxide, α-flupenthixol and behavioural manipulations on choice of signalled and unsignalled delayed reinforcement in rats , 2000, Psychopharmacology.

[25]  J E Steinmetz,et al.  Decision-making biases, antisocial personality, and early-onset alcoholism. , 2000, Alcoholism, clinical and experimental research.

[26]  Carlo Contoreggi,et al.  Drug abusers show impaired performance in a laboratory test of decision making , 2000, Neuropsychologia.

[27]  T. R. Wade,et al.  Effects of dopaminergic drugs on delayed reward as a measure of impulsive behavior in rats , 2000, Psychopharmacology.

[28]  H. de Wit,et al.  Effects of methamphetamine on the adjusting amount procedure, a model of impulsive behavior in rats , 1999, Psychopharmacology.

[29]  R. Suckow,et al.  Branched chain amino acids decrease tardive dyskinesia symptoms , 1999, Psychopharmacology.

[30]  W. Bickel,et al.  Shortened time horizons and insensitivity to future consequences in heroin addicts. , 1998, Addiction.

[31]  A. Damasio,et al.  Deciding Advantageously Before Knowing the Advantageous Strategy , 1997, Science.

[32]  A. Damasio,et al.  Insensitivity to future consequences following damage to human prefrontal cortex , 1994, Cognition.

[33]  R. L. Brunner,et al.  Valine, isoleucine, and leucine. A new treatment for phenylketonuria. , 1990, American journal of diseases of children.

[34]  N. Andreasen.  The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations , 1989, British Journal of Psychiatry.

[35]  N. Mimica,et al.  Scale for the Assessment of Negative Symptoms (SANS)* , 1989, British Journal of Psychiatry.

[36]  N. Risch,et al.  The continuous performance test, identical pairs version (CPT-IP): I. new findings about sustained attention in normal families , 1988, Psychiatry Research.

[37]  G. V. Goddard,et al.  Cognitive and motor dysfunction in Parkinson's disease. Clinical, performance, and computed tomographic correlations. , 1988, Archives of neurology.

[38]  M. Le Moal,et al.  Alternation behavior, spatial discrimination, and reversal disturbances following 6-hydroxydopamine lesions in the nucleus accumbens of the rat. , 1985, Behavioral and neural biology.

[39]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.

[40]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[41]  Stephen M. Stahl,et al.  A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. , 2004, Primary care companion to the Journal of clinical psychiatry.

[42]  J. Busemeyer,et al.  A contribution of cognitive decision models to clinical assessment: decomposing performance on the Bechara gambling task. , 2002, Psychological assessment.

[43]  P. Goldman-Rakic,et al.  Functional and anatomical aspects of prefrontal pathology in schizophrenia. , 1997, Schizophrenia bulletin.

[44]  R. R. Abidin.  Psychological Assessment Resources , 1995 .

[45]  M. Woerner,et al.  Anchoring the BPRS: an aid to improved reliability. , 1988, Psychopharmacology bulletin.

[46]  J. Overall.  The brief psychiatric rating scale (BPRS) : Recent developments in ascertainment and scaling. Introduction , 1988 .

[47]  G. Marchesini,et al.  Plasma clearances of branched-chain amino acids in control subjects and in patients with cirrhosis. , 1987, Journal of hepatology.

[48]  R. Miller,et al.  Branched-chain amino acid metabolism. , 1984, Annual review of nutrition.